Please login to the form below
Sialanar
This page shows the latest Sialanar news and features for those working in and with pharma, biotech and healthcare.
HIV prevention pill heads July CHMP recommendations
The CHMP reversed an earlier negative opinion on Proveca's Sialanar (glycopyrronium bromide) as a treatment for severe drooling in children and adolescents with neurological disorders, backing it under a paediatric
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- New study identifies drugs that are safe to use in COVID-19 treatment
- Keytruda doubles five-year survival rate in NSCLC
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
